Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00085696
Other study ID # M34103-061
Secondary ID
Status Completed
Phase Phase 2
First received June 11, 2004
Last updated February 7, 2008
Start date May 2004

Study information

Verified date February 2008
Source Millennium Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date
Est. primary completion date April 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female subject 18 years or older

- Diagnosis of B-cell lymphoma (CD20+) of

- follicular lymphoma (grades 1, 2, and 3) or

- marginal zone lymphoma (extranodal, nodal, and splenic)

- Documented relapse or progression following prior anti-neoplastic treatment.

- At least 1 measurable lymph node mass that is >1.5 cm.

- No active CNS lymphoma

- Voluntary consent

Exclusion Criteria:

- Previous treatment with VELCADE

- Any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug.

- Any treatment with nitrosoureas within 6 weeks before the first dose of study drug.

- Treatment with Zevalin™ or Bexxar® within 10 weeks before the first dose of study drug.

- Rituximab, Campath® or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug.

- Radiation therapy within 3 weeks before the first dose of study drug.

- Major surgery within 2 weeks before the first dose of study drug.

- Peripheral neuropathy or neuropathic pain

- History of allergic reaction attributable to compounds containing boron or mannitol

- Known anaphylaxis or hypersensitivity to any component of rituximab

- Diagnosed or treated for a selected malignancies other than NHL within 5 years.

- Active systemic infection requiring treatment

- Female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study.

- Male subjects who do not agree to use an acceptable method of contraception for the duration of the study

- Any serious medical or psychiatric illness likely to interfere with participation in this clinical study

- Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
VELCADE and rituximab


Locations

Country Name City State
United States Emory University Cancer Institute, Winship Cancer Institute Atlanta Georgia
United States Charleston Cancer Center Charleston South Carolina
United States Rush University Medical Center Chicago Illinois
United States Mid Ohio Oncology/Hematology Inc. Columbus Ohio
United States FNVHO - US Oncology Fairfax Virginia
United States Florida Cancer Specialists Fort Myers Florida
United States MD Anderson Cancer Center Houston Texas
United States Oncology/Henmatology Associates of Kansas City Kansas City Missouri
United States UCLA School of Medicine Los Angeles California
United States Georgia Cancer Specialists Marietta Georgia
United States University of Utah, Huntsman Cancer Institute Salt Lake City Utah
United States Midwest Cancer Research Group Skokie Illinois
United States Cancer Center of Kansas Wichita Kansas

Sponsors (1)

Lead Sponsor Collaborator
Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03078855 - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Phase 3
Active, not recruiting NCT03245021 - Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A Phase 1
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02213263 - A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Phase 3
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Terminated NCT00772668 - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL N/A
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Terminated NCT02204982 - Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma Phase 3
Terminated NCT00850499 - Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab Phase 2
Completed NCT02536664 - Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Terminated NCT00136591 - A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma Phase 2
Not yet recruiting NCT06068881 - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Phase 2
Completed NCT04034056 - Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)